Four new drugs are expected to be launched in China in this period: Amgen/Takeda's Vectibix, Bayer's Stivarga, Sanofi's Zaltrap, and Taiho Pharmaceutical's Lonsurf, with Bayer's drug expected to ...
The second part was for fourth-line use in GIST patients, and the agency decided it wanted to see the results of an ongoing phase 3 trial comparing Ayvakit to Bayer’s Stivarga (regorafenib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback